MedCity News February 13, 2025
GLP-1 drugs dominate the obesity market, but Aardvark Therapeutics aims to curb appetite by going after a different target: TAS2 receptors in the gut. The biotech’s lead drug candidate is in Phase 3 testing in Prader-Willi syndrome, a genetic disorder that causes persistent hunger leading to overeating.
The obesity drugs currently available address a broad swath of patients who struggle to manage their weight. While Aardvark Therapeutics is interested in serving this market, first it wants to validate its approach by treating patients whose excessive eating is rooted in a rare genetic disorder. Aardvark’s lead program is in pivotal testing and the biotech now has $94.2 million in IPO cash for clinical research.
Aardvark late Wednesday priced 5.88 million shares...
Today's Sponsors
Today's Sponsor